

ESR1 Mutations in Breast Cancer

Derek Dustin, BS^{1,2}; Guowei Gu, PhD^{1,3,4}; and Suzanne A. W. Fuqua, PhD^{1,3,4}

The acquisition of ligand-independent *ESR1* mutations during aromatase inhibitor therapy in metastatic estrogen receptor (ER)-positive breast cancer is a common mechanism of hormonal therapy resistance. Preclinical and clinical studies have demonstrated that *ESR1* mutations can preexist in primary tumors and can be enriched during metastasis. Furthermore, *ESR1* mutations express a unique transcriptional profile that favors tumor progression, suggesting that selected *ESR1* mutations may influence metastasis. Several groups have used sensitive detection methods using patient liquid biopsies to track *ESR1* or truncal somatic mutations to predict treatment outcome and tumor progression, and some of these techniques may eventually be used to guide sequential treatment options in patients. Further development and standardization of mutation tracking in circulating tumor DNA is ongoing. Clinically, patients with *ESR1* mutations derive clinical benefit when treated with fulvestrant and CDK4/6-targeted therapies, but the development of more potent selective ER degraders and/or new targeted biotherapies are needed to overcome the endocrine-resistant phenotype of *ESR1* mutant-bearing tumors. In this review, we discuss the mechanisms of resistance and dissemination of *ESR1* mutations as well as the detection methods for *ESR1* mutation tracking, newly discovered potential therapeutic targets, and the clinical implications and treatment options for treating patients with *ESR1* mutant-bearing tumors. **Cancer 2019;125:3714-3728.**
© 2019 American Cancer Society.

KEYWORDS: breast cancer, estrogen receptor, metastasis, mutation.

INTRODUCTION

Approximately 70% of breast cancers are estrogen receptor (ER)-positive, and many of these patients are effectively cured of their disease.¹ However, despite effective hormonal and targeted therapies, half of these patients will relapse or progress to incurable metastatic disease. Several mechanisms of de novo and acquired endocrine therapy (ET) resistance have been described, including loss of ER expression, ER crosstalk with growth factor receptors, subclonal genomic alterations of tumor suppressors or drivers, and acquisition of *ESR1* fusions or activating *ESR1* missense mutations.²⁻⁴

Current clinical strategies to effectively treat and prevent recurrence of ER-positive breast cancer is with ETs, which target the ER through hormone deprivation or antagonistic binding of the receptor. ET cures about half of patients in the nonmetastatic setting, and clinical benefit is seen in about 30% of metastatic patients. However, most metastatic breast cancer (MBC) patients will eventually progress on ET and succumb to their disease. Other targeted agents such as the CDK4/6 inhibitors palbociclib, ribociclib, or abemaciclib, and the mammalian target of rapamycin (mTOR) inhibitor everolimus are combined with ET in the metastatic setting, as these agents have shown improved progression-free survival (PFS) in patients compared with ET alone.⁵⁻⁸ However, patients with *ESR1* mutant-positive metastases are resistant to standard-of-care ET and exhibit a worse overall survival.^{9,10} Figure 1 shows the location within the ER where these mutations occur in clinical samples. The most common and well-characterized mutations occur at the Y537 and D538 residues. However, missense mutations have been identified in at least 51 other residues, most of which occur within the ER ligand-binding domain (LBD). The most common mutations have been functionally characterized as hormone-independent activating mutations (Y537, D538), whereas others result in estrogen hypersensitivity (K303R, E380Q)^{11,12} or neutral, retaining hormone-dependent activation function (S432L, V534E).¹² Furthermore, many of these mutations are rare and have not yet been functionally annotated. There is a current clinical need to identify additional effective hormonal and targeted therapies, as well as novel therapeutic sequencing strategies to best treat MBC. This review focuses on the biology, detection, and treatment strategies of *ESR1* LBD mutations as one of the most common mechanisms of acquired endocrine resistance.

Corresponding author: Suzanne A. W. Fuqua, PhD, Lester and Sue Smith Breast Center, BCM 600, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030; sfuqua@bcm.edu

¹Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas; ²Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas; ³Department of Medicine, Baylor College of Medicine, Houston, Texas; ⁴Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas

DOI: 10.1002/cncr.32345, **Received:** April 24, 2019; **Revised:** May 24, 2019; **Accepted:** May 28, 2019, **Published online** July 18, 2019 in Wiley Online Library (wileyonlinelibrary.com)




Figure 1. Location of *ESR1* missense mutations found in clinical samples. Of 62 identified mutations, 47 occurred in the ligand binding domain, and several were associated with ligand-independent activation of estrogen receptor. AF1, activation function 1; AF2, activation function 2; DBD, DNA binding domain; LBD, ligand binding domain. Data obtained from COSMIC (<https://cancer.sanger.ac.uk/cosmic>) and cBioPortal for Cancer Genomics (<https://www.cbioportal.org/>). Accessed March 11, 2019.

BIOLOGY OF *ESR1* MUTATIONS IN PRECLINICAL STUDIES

Several studies have shown that *ESR1* LBD mutations are constitutively active and are less sensitive to the ER antagonists tamoxifen and fulvestrant.¹³⁻¹⁶ In vitro studies have shown that the Y537S and D538G mutations required higher concentrations of antagonist to decrease ER signaling compared with the wild-type (WT) receptor. Molecular modeling of the Y537S and D538G *ESR1* LBD mutations showed that these mutations are in an apo-receptor conformation and are constitutively active, even upon antagonist binding.^{15,17} These mutations induced changes in protein structure, which resulted in reduced ligand affinity, and this may be one potential mechanism for their ligand-independent activity and ET resistance. In the absence of ligand, the mutant receptors exhibited increased hydrogen bonding between Y537S and N348, which was similar to the estrogen-bound WT receptor. Mutant receptors also had enhanced protein stability compared with the WT receptor when bound to fulvestrant. Several studies have shown that the most common *ESR1* LBD mutations also recruited coactivators, such as SRC-1 and SRC-3, in the absence of ligand that further potentiated ER transcription.^{18,19} Therefore, it was concluded that the altered structure of *ESR1* mutations conferred ET resistance and potentiated distinct mechanisms of resistance through enhanced coactivator recruitment.

The transcriptomes of WT and mutant ERs have been described by several groups, showing there are

shared, classical ER signaling signatures, as well as mutant-specific transcriptional regulation.²⁰⁻²² Using in vitro-derived *ESR1* mutant cell line models generated using CRISPR/Cas9 technology, or through natural selection of cells in hormone-deprived conditions, Martin et al²³ showed that there was a high overlap between ER chromatin binding sites of estrogen-stimulated WT receptor and hormone-deprived mutant receptors. They further showed that estrogen treatment of both the WT and Y537S models exhibited a 74% concordance in ER binding sites. These results suggest that there are hormone-dependent but also independent mechanisms of mutant gene regulation and that the unique constitutive mutant-specific ER binding sites and transcriptional regulation should be studied further to better understand the role of the *ESR1* mutant in tumor growth and progression.

Recent studies by Jeselsohn et al²⁰ demonstrated that the models expressing the Y537S mutation was relatively more resistant to growth inhibition when treated with tamoxifen or fulvestrant compared with D538G and WT, which is consistent with many published studies. The Y537S and D538G mutations exhibited different cistromes and transcriptomes compared with WT *ESR1*. Specifically, gene expression analyses comparing estrogen-bound WT receptor with hormone-deprived Y537S and D538G mutant receptors showed little overlap of shared gene expression (18% and 33%, respectively). Furthermore, there was minimal upregulation of gene expression when Y537S mutant cells were treated

with estrogen (12 genes), but there was a significant increase in gene expression when D538G mutant-expressing cells were treated with estrogen (416 genes), and many of these genes were unique to each mutation. Transcriptome analysis of MBC patient tumors harboring *ESR1* mutations showed a high correlation with profiles obtained from these cell line models as analyzed by gene set enrichment analysis, validating the significance of the in vitro–derived models. Collectively, these data demonstrate that *ESR1* mutations mediate unique and allele-specific transcriptional programs that do not just mimic estrogen-regulated WT ER expression. A better mechanistic understanding of how mutant receptors drive unique gene expression in metastatic disease could provide insight into not only the subclonal evolution of *ESR1* mutants, but may also identify novel strategies to target tumor progression.

Other studies have extended clinical findings of acquired *ESR1* mutations in hormone-deprived MBC patients by confirming these observations in 2-dimensional culture systems. For instance, Martin et al²³ were the first to model in vitro the natural acquisition of *ESR1* mutations in ER-positive breast cancer cells. Culturing breast cancer cells with WT *ESR1* for the long term in hormone-depleted media resulted in gradual acquisition of the Y537C mutation in MCF-7 cells and the Y537S mutation in SUM44 cells. Interestingly, analysis of parental cells from each line demonstrated that a subpopulation of Y537S mutant cells preexisted in SUM44 cells at a very low frequency, and that this population was then enriched with long-term estrogen-deprived in vitro conditions. The Y537C mutation was not identified in the parental MCF-7 cells, suggesting that these mutations can either preexist or be acquired depending on the cell line background. Furthermore, tamoxifen- or fulvestrant-resistant long-term treated cell lines did not acquire *ESR1* mutations, further supporting clinical evidence that most tumors acquiring *ESR1* mutations did so during estrogen withdrawal with AIs. Integrated transcriptomic and cistromic analyses demonstrated that the cell line models with naturally occurring *ESR1* mutations exhibited enriched chromatin binding, which correlated with enhanced estrogen-independent transcriptional activity. These results in long-term estrogen-deprived models are also confirmatory of studies that used CRISPR/Cas9 knock-in or lentiviral engineered *ESR1* mutation models.^{20,23}

Nongenomic functions of *ESR1* mutations have also been described. Gelsomino et al¹⁴ have shown that insulin growth factor 1 receptor (IGF-1R) signaling was

upregulated in *ESR1* mutant overexpression models, and was involved in ET resistance to tamoxifen. Interestingly, this mechanism of resistance was cell-type specific and was dependent on the expression of the PI3K regulators, *PI3K3R1* and *PI3K3R3*, since small interfering RNA knockdown of these regulators restored tamoxifen sensitivity. Treatment with specific inhibitors of the IGF-1R pathway also sensitized *ESR1* mutant cells to tamoxifen. Furthermore, ER immunoprecipitation and proximity ligation assays demonstrated enhanced co-localization and crosstalk between mutant ER and IGF-1R.⁴ More recently, Li et al²⁴ confirmed a role for the IGF-1R pathway using similar mutant models. RNA-Seq analyses showed an enhanced IGF gene signature in the mutant models compared with WT receptor expressing models. These cells exhibited an enhanced growth response to IGF1, which was common between the mutant models but also between tamoxifen-resistant and long-term estrogen-deprived models. Targeting the IGF-1R pathway through small interfering RNA knockdown or targeted inhibitors sensitized *ESR1* mutant cells to ET, as demonstrated in the study by Gelsomino et al.¹⁴ Unfortunately, IGF-1R inhibitors have not yet proven clinically useful in MBC; therefore, they are currently not a viable targeted clinical approach for patients with *ESR1* mutations. Other growth factor receptors, including the HER1-3 family members, need to be evaluated as potential mechanisms of ET resistance in *ESR1* mutation models, since expression of different growth factor receptor family members have been shown to be enhanced in these models.^{14,24}

Martin et al²³ performed rapid immunoprecipitation with tandem mass spectrometry of endogenous proteins to delineate *ESR1* WT and mutant interactomes. These analyses demonstrated that many of the proteins bound by mutant *ESR1* were also bound by WT *ESR1*, but that there were increased interactions between mutant receptors and selected transcriptional regulators, such as GREB1 and FOXA1. ChIP-Seq analyses also demonstrated a ligand-independent enrichment of FOXA1 motifs in *ESR1* mutant cells. Targeted knockdown of FOXA1 in WT and mutant cells resulted in a greater growth inhibition in *ESR1* mutant cells compared with WT, suggesting a role for FOXA1 in mutant-specific biology. In contrast, Jeselsohn et al²⁰ found that the FOXA1 motif was not enriched in hormone-deprived Y537S cells compared with estrogen-treated WT cells, and that knockdown of FOXA1 did affect growth of mutant *ESR1* cells compared with WT cells. These discordant findings could be explained by different treatment conditions between the groups, different modeling of

ESR1 mutations through CRISPR/Cas9 or overexpression systems, or divergent cellular backgrounds. Studies of the interactome of mutant *ESR1* from clinical samples needs to be more thoroughly studied, as these may help resolve these discrepancies and potentially identify new approaches for targeting direct, mutant-specific transcriptional regulators in *ESR1* mutant samples.

Implications of *ESR1* Mutations in Metastasis and Tumor Progression

There is considerable preclinical and clinical evidence demonstrating that metastatic tumor cells with *ESR1* mutations are most frequently acquired under the selective pressure of aromatase inhibitor (AI) therapy.^{20,25} These mutations are rare or are not present in primary tumors. *ESR1* mutant cells may display an enhanced “aggressive phenotype,” which could provide an enrichment of subclonal cell populations in circulating tumor cells and metastatic sites.^{10,26}

Gu et al²⁵ were the first to report that the Y537S *ESR1* mutation drives spontaneous ligand-independent distant metastasis in vivo using CRISPR-Cas9 engineered *ESR1* mutant xenograft models. Jeselsohn et al²⁰ recently used doxycycline-inducible models of the Y537S and D538G *ESR1* mutations to show that these cells express a transcriptional network that promotes metastasis. *ESR1* Y537S and D538G mutant cells both metastasized, and withdrawal of doxycycline in the Y537S models resulted in regression of metastatic tumors, demonstrating that metastases resulted from mutant ER populations. Transcriptional profiling from this and other studies have shown that *ESR1* mutations promote upregulation of hallmark cancer pathways, including estrogen response, the p53 pathway, and MTORC1 signaling, suggesting a role for mutant ERs in promoting an ET-resistant and metastatic phenotype.^{20,23}

SENSITIVE DETECTION METHODS FOR *ESR1* MUTATIONS IN CLINICAL BIOPSIES

It has been reasoned that the detection of *ESR1* mutations in clinical samples could provide important prognostic information over the treatment course of ER-positive metastatic disease. ER-positive breast cancer patients can recur many years after completion of adjuvant therapy. Zhang et al¹³ were the first to identify an *ESR1* mutation, Y537N, in a metastatic ER-positive tumor biopsy in 1997 using ER-specific exon primer polymerase chain reaction (PCR) and Sanger sequencing. Fifteen years after this seminal discovery, many laboratories have now confirmed the

presence of *ESR1* mutations in MBC biopsy samples using deep sequencing, and collectively these studies have identified a hotspot for *ESR1* mutations within the LBD region using various DNA sequencing methods.^{9,10,12,15,16,26-28} Early studies using next generation sequencing (NGS) as the detection method for *ESR1* mutations found that mutations were relatively rare in clinical samples. However, the development of droplet digital PCR (ddPCR) technology has allowed for more sensitive and reliable detection of these mutations. With current data, it is thought that the acquisition of *ESR1* mutations are the most common mechanism of ET resistance in MBC. One of the challenges in breast cancer is the development of prognostic and predictive biomarkers for monitoring MBC patients. Next, we discuss the different sequencing approaches that have been developed recently using retrospective analysis of clinical trial samples to evaluate the emergence of *ESR1* mutations during tumor progression.

NGS DETECTION OF *ESR1* MUTATIONS IN PATIENT BIOPSIES

Some of the early studies that analyzed *ESR1* mutations from clinical samples used NGS platforms. NGS using Illumina HiSeq 2000 technology identified lower mutation frequencies of 25% (9/36) and 11% (5/44) in 2 independent cohorts of MBC patient tumors.¹⁵ Only 3% (6/183) of primary tumors contained *ESR1* mutations, providing some of the first data that these mutations may emerge during metastasis. NGS of sequential tumor biopsies over time would allow for the identification of genomic alterations as potential mechanisms of tumor progression, but the burden of multiple biopsies on patients, and the cost and complexity of the assay over other techniques (eg, targeted ddPCR) limits its routine use as a standardized assay for patient management.

The Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) panel was developed as an alternative to NGS to detect selected common cancer gene mutations with high sensitivity.⁴ Using this mutational profiling technology, *ESR1* mutation status was analyzed in archival samples from a cohort of 929 breast cancer patients who were treated at Memorial Sloan Kettering Cancer Center. In this analysis, mutations were found in 3.5% (11/313) of primary breast tumors and 13.6% (84/616) of metastatic tumors. Furthermore, *ESR1* mutations were found in ER-positive samples, but not triple-negative cancers.¹² *ESR1* mutations were also identified in 7.9% (10/126) of ER-positive/HER2-positive patients,

suggesting that *ESR1* mutations might also play a role in HER2 patients who undergo HER2-targeted therapy; therefore, further investigation will be needed to evaluate *ESR1* mutant-specific biology in a HER2-positive background to determine whether patients with mutations have a different treatment outcome.

Additional studies using the MSK-IMPACT platform compared genomic alterations between early breast cancer and MBC.²⁹ These analyses demonstrated that ER-positive, but not HER2-positive or triple-negative breast cancers, had a significant enrichment of additional driver mutations in metastatic tumors compared with early breast cancer. Some of these mutated genes are downstream of ER regulation or are involved in the regulation of ER itself, including the transcriptional regulators *KMT2C*, *NCOR1*, and *AKT1*. These findings suggest that *ESR1* mutant-positive breast cancers evolve and acquire distinct and perhaps targetable mechanisms driving tumor evolution that directly affect or are a consequence of ER signaling.

DDPCR DETECTION OF *ESR1* MUTATIONS IN PATIENT BIOPSIES

ddPCR technologies are increasingly being used to detect *ESR1* mutations in both solid tumor and liquid biopsies due to the enhanced sensitivity and lower cost compared with NGS technology. Thus the increased sensitivity of ddPCR is allowing for more accurate positive detection of *ESR1* mutations from patient biopsies. Takeshita et al³⁰ were one of the first groups to evaluate *ESR1* mutation status (Y537S, D538G, Y537N, or Y537C) from formalin-fixed, paraffin-embedded samples (270 primary and 55 MBC tumors), and reported *ESR1* mutation frequencies of 2.5% and 20%, respectively. Of the 11 MBC patients with *ESR1* mutations, 5 had been treated with an AI, 4 were treated with tamoxifen, and 2 had not had received prior ET before biopsy. Furthermore, Gelsomino et al¹⁴ analyzed *ESR1* mutation status in a larger cohort of 203 primary breast cancers treated with tamoxifen monotherapy, and found that the frequency of *ESR1* mutations was higher (12% Y537N, 5% Y537S, and 2% for the D538G mutations) compared to other reports in the literature of unselected primary tumors. In addition, the presence of *ESR1* mutations was associated with a better progression free survival in these tamoxifen-treated patients, suggesting that the use of tamoxifen might not select for or may be effective at preventing the emergence of mutation. This possibility needs to be explored.

In the CARMINA02 clinical trial, which evaluated the efficacy of neoadjuvant anastrozole versus fulvestrant, *ESR1* mutations were found in 3.4% (3/89) of treatment-naïve tumors.³¹ Technologies for assessing liquid biopsies have also recently been developed, and have there are now commercial assays to monitor *ESR1* mutation status in metastatic patients. Schiavon et al²⁶ used ddPCR of liquid biopsy samples from advanced breast cancer patients but did not detect *ESR1* mutations in a cohort of 22 patients who were previously treated with tamoxifen in an adjuvant setting; however, they detected *ESR1* mutation frequencies in 0% (0/32) to 5.8% (3/52) in 2 cohorts of patients who were treated with an AI in an adjuvant setting. Mutation frequencies were enriched to 36.4% (16/44) in patients who were treated with an AI in the metastatic setting. These data demonstrate that *ESR1* mutations can preexist at low frequencies in primary tumors but are enriched in a metastatic setting, especially in AI-treated patients.

Whether the analysis of circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) will become a superior technical approach to detect *ESR1* mutations, and monitor treatment response or progression is still being evaluated. Shaw et al³² compared paired CTCs and ctDNA samples from the same patient cohort. More mutations were discovered in ctDNA than the paired CTC sample, and not all CTCs had the same mutations that were found in the ctDNA. This finding suggests that ctDNA analyses may be more sensitive for tracking gene mutations rather than CTCs. However, there is a need to evaluate mutations in liquid biopsies to those found in distant metastatic tumors biopsies to draw definitive conclusions about discordances. Thus, digital PCR using liquid biopsies has been applied to evaluate *ESR1* mutation frequencies in several large phase 2/3 clinical trials such as BOLERO 2, SoFEA, PALOMA3, and FERGI.^{9,10,28} With increasing use, the potential advantages of ctDNA versus CTC sampling should become apparent.

In the BOLERO-2 clinical trial, MBC patients who had prior exposure to a nonsteroidal AI were randomized to the steroidal AI exemestane, or in combination with the mTOR inhibitor everolimus.³³ Y537S and D538G *ESR1* mutations were found in 29% (156/541) of patients.¹⁰ Thirty patients exhibited polyclonal Y537S and D538G mutations, and other studies have also confirmed that *ESR1* mutations are frequently polyclonal.^{9,28,34-37} Survival analyses showed that patients with Y537S or D538G mutations exhibited worse overall survival compared with patients who had only WT ER (32.1 vs 20.7 months). Patients with polyclonal

ESR1 mutations also exhibited a worse overall survival (15.2 months). Treatment with everolimus was associated with improved PFS for patients with the D538G mutation that was similar to WT (5.78 months for D538G, 8.48 months for WT), but the analysis of PFS in patients with the Y537S mutation was underpowered to determine whether clinical benefit was achieved in this treatment arm. A potential limitation of this study was that only 2 *ESR1* mutations were assessed using ddPCR, and the acquisition of other polyclonal *ESR1* mutations may have impacted the prognostic results obtained in this trial.

Fribbens et al⁹ developed a multiplex ddPCR assay to simultaneously study 7 *ESR1* mutations in ctDNA from the SoFEA and PALOMA3 clinical trials. In the SoFEA clinical trial, patients who exhibited prior sensitivity to nonsteroidal AIs were randomized to receive fulvestrant plus anastrozole, fulvestrant plus placebo, or the steroidal AI exemestane.³⁸ In this cohort of patients, *ESR1* mutations were found in 39.1% (63/161) of patient's ctDNA, and 49.1% (27/55) of these patients exhibited polyclonal mutations. Patients who had an *ESR1* mutation and were treated with exemestane had worse PFS compared with patients who did not have detectable *ESR1* mutations (2.6 vs 8.0 months). Patients who were treated with fulvestrant derived significant clinical benefit regardless of whether they had detectable *ESR1* mutations (PFS 5.7 months for *ESR1* mutations, 5.4 months for WT ER). Therefore, this study suggests that patients with *ESR1* mutations were relatively sensitive to a fulvestrant-containing regimen and should be treated with fulvestrant if there were detectable *ESR1* mutations.

In the PALOMA-3 clinical trial, patients who progressed during ET were randomized to receive fulvestrant or fulvestrant plus palbociclib.⁵ *ESR1* mutations were detected in 25.3% (91/360) of the patients in this cohort. Patients with *ESR1* mutations had improved PFS when treated with fulvestrant plus palbociclib versus fulvestrant monotherapy (9.4 vs 3.6 months), as well as patients with WT *ESR1* (9.5 vs 5.4 months). These results suggest that patients who have progressed on a nonsteroidal AI derive clinical benefit from fulvestrant and palbociclib, regardless of whether the patient ctDNA exhibited *ESR1* mutations. However, a more recent analysis of the PALOMA-3 clinical trial demonstrated that although there was no overall enrichment of *ESR1* mutations during treatment, the Y537S mutation was selectively enriched in fulvestrant-based treatments in the metastatic setting, suggesting relative resistance to fulvestrant and palbociclib.³⁹

In the FERGI clinical trial, AI-resistant, locally advanced, or MBC patients were treated with fulvestrant alone or in combination with the pan-PI3K inhibitor pictilisib.⁴⁰ BEAMing Digital PCR assays were developed to detect 12 *ESR1* mutations using ctDNA. Liquid biopsies were evaluated at progression on an AI, and *ESR1* mutations were found in 37% (57/153) of patient ctDNA.²⁸ The authors also compared ctDNA data with those found using tumor tissue from a subset of the patients. No *ESR1* mutations were detected in primary tumor tissue from biopsies collected at diagnosis (0/81). However, 9.7% (3/31) of metastatic samples obtained before AI therapy contained *ESR1* mutations, and the prevalence increased to 63% (12/19) in tumor samples collected after AI progression. In patients with both ctDNA and tumor tissues, the ctDNA often showed increased *ESR1* mutant content than match tumor tissue. This suggests that ctDNA might better reflect the total *ESR1* mutation burden across multiple metastatic sites.

There was no significant difference in PFS between patients according to *ESR1* mutation status in both the fulvestrant only or the combination fulvestrant plus pictilisib arms of FERGI. These findings support that patients derive benefit from fulvestrant treatment regardless of *ESR1* mutation status when mutations are analyzed in aggregate. This is in contrast to the retrospective analysis of PALOMA-3,⁵ where end of treatment ctDNA was used to demonstrate that the Y537S was significantly increased and associated with resistance to fulvestrant or fulvestrant plus palbociclib.

Collectively, these results demonstrate a need for the routine use of targeted sequencing of liquid biopsies, and if possible, tumor samples. These collective results show that *ESR1* mutations represent a small subclonal population in primary breast tumors that are most probably enriched during the course of treatment in the metastatic setting. Table 1 summarizes the frequencies of *ESR1* mutations found in clinical tumor biopsies. These frequencies show that overall, the use of ctDNA may be a more reliable and representative detection of total *ESR1* mutation status compared with genomic DNA from primary or metastatic tumors.

CLINICAL IMPLICATIONS AND THERAPEUTIC STRATEGIES TO TREAT MBC WITH *ESR1* MUTATIONS

There are effective ETs to treat patients with ER-positive metastatic disease. ET and biotherapy combinations are now commonly used to treat ET-resistant MBC, as opposed to sequencing of single endocrine agents. There

TABLE 1. *ESR1* Mutation Frequency in Primary or Metastatic Tumors, or ctDNA

Reference	Sequencing Method	<i>ESR1</i> Mutation Prevalence	Mutations Detected
Primary tumor			
Toy et al ¹⁵	NGS	3.3% (6/183)	E380Q, V392I, L536R, Y537C, Y537N, D538G
Toy et al ¹²	Targeted sequencing	3.5% (11/313)	S329Y, G344D, E380Q, V418E, S463P, S432L, F461D, L466Q, V478L, N532K, V534E, L536H, L536P, L536R, Y537S, Y537N, Y537C, Y537D, D538G, E542G, A576D
Liang et al ³¹	ddPCR	3.4% (3/89)	Mutations not specified
Metastatic tumor			
Toy et al ¹²	Targeted sequencing	14% (84/616)	S329Y, G344D, E380Q, V418E, S463P, S432L, F461D, L466Q, V478L, N532K, V534E, L536H, L536P, L536R, Y537S, Y537N, Y537C, Y537D, D538G, E542G, A576D
Toy et al ¹⁵	NGS	25% (9/36) and 11% (5/44)	S463P, V534E, L536R, Y537N, Y537S, D538G
Robinson et al ¹⁶	NGS	55% (6/11)	L536Q, Y537S, D538G
Takeshita et al ³⁶	ddPCR	17% (6/35)	Y537C, Y537N, Y537S, D538G
ctDNA			
Schiavon et al ²⁶	ddPCR	14% (24/171) 4.1% (2/49) 22% (4/18)	L536R, Y537C, Y537N, Y537S, D538G
Clatot et al ²⁷	ddPCR	31% (44/144)	Y537C, Y537N, Y537S, D538G
Spoerke et al ²⁸	ddPCR	37% (57/153)	E380Q, S463P, P535H, L536Q, L536R, L536H, L536P, Y537C, Y537N, Y537S, D538G
Chandarlapaty et al ¹⁰	ddPCR	29% (156/541)	Y537S, D538G
Fribbens et al ⁹	ddPCR	39% (63/161) and 25% (91/360)	E380Q, S463P, L536R, Y537C, Y537N, Y537S, D538G
Chung et al ³⁵	NGS	34% (67/197)	T347A, R352M, H356D, M357V, L379I, E380Q, M388I, M388L, T431S, G442R, S463P, H476N, H524L, H524Y, P535T, L536F, L536H, L536P, L536R, L536V, Y537S, Y537N, Y537C, Y537D, D538G, L539P, L541M, E542D, E542K
Takeshita et al ³⁶	ddPCR	14% (5/35)	Y537C, Y537N, Y537S, D538G
Cristofanilli et al ⁴¹	BEAMing ddPCR	27% (106/396)	Mutations not specified
O'Leary et al ⁴²	ddPCR	31% (61/195)	E380Q, S463P, L536R, Y537C, Y537N, Y537S, D538G
Lok et al ⁴³	ddPCR	30% (10/33)	E380Q, S463P, I514V, Y537C, Y537S, D538G
Allouchery et al ⁴⁴	ddPCR	33% (7/21)	Y537C, Y537N, Y537S, D538G
Fribbens et al ³⁴	ddPCR	56% (22/39)	E380Q, S463P, L536R, Y537C, Y537N, Y537S, D538G

Abbreviations: ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction; NGS, next generation sequencing.

are 2 biological targets that have been approved for ER-positive breast cancer: mTOR and cyclin-dependent kinases (CDKs) 4/6. Treatment guidelines recommend that patients who develop MBC 12 months after adjuvant ET or who are de novo metastatic should be treated in a first-line setting with an AI in combination with a CDK4/6 inhibitor.⁴⁵ This recommendation is based on the results of the PALOMA-2 trial, which showed that the combination of letrozole and palbociclib extended PFS by 13.1 months compared with letrozole alone (27.6 vs 14.5 months).⁴⁶ However, other approaches, such as the selective estrogen receptor degrader fulvestrant alone or in combination with a CDK4/6 inhibitor, are also often used in a first-line metastatic setting. Subsequent therapy of an AI- and/or CDK4/6 inhibitor-treated patient includes fulvestrant monotherapy (or in combination with a CDK4/6 inhibitor in treatment-naïve patients), a steroidal AI with or without an mTOR inhibitor, tamoxifen, or chemotherapy. Preclinical development and proof of clinical utility of additional targeted biotherapies are needed to delay the eventual progression to unresponsive

metastatic disease. A better understanding of when to use targeted therapies and the sequence of combination therapies is critical to effectively manage ER-positive disease. Importantly, there has not been a direct comparison of the efficacy of fulvestrant monotherapy versus an AI with a CDK4/6 inhibitor. Furthermore, there has not been a direct comparison between the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in clinical trials. These comparisons will help us understand effective sequencing of therapies to delay acquired resistance to targeted therapies and manage metastatic disease.

Current treatment guidelines for ER-positive MBC do not stratify patients based on *ESR1* mutation status. Although many preclinical studies have demonstrated that *ESR1* mutant cells respond to fulvestrant, but with less sensitivity, recent retrospective analyses of the PALOMA-2 clinical trial published by O'Leary et al³⁹ trial showed that patients treated with fulvestrant monotherapy alone, or in combination with palbociclib continued to acquire the Y537S *ESR1* mutation during treatment. Furthermore, a more recent retrospective

correlative analysis of the PALMOA-3 trial evaluated whether early changes in *ESR1* or *PIK3CA* mutations measured using ddPCR of ctDNA were predictive of response to therapy. Although total *ESR1* mutant abundance was shown to decrease in both treatment arms, these changes were not predictive of response to fulvestrant.⁴² In contrast, *PIK3CA* mutation frequency was lower in the fulvestrant and palbociclib-treated group and was significantly predictive of PFS. This study suggests that truncal mutations, such as *PIK3CA*, may be more useful to predict treatment responses. Differences in the predictive value of these 2 genetic biomarkers may be due to the clinical resistance of selected *ESR1* mutant cells to fulvestrant and the truncal nature of *PIK3CA* mutations that are shared by all subclones in the metastatic tumor. O'Leary et al also showed that other driver mutations in *RBI*, growth factor receptors, *TP53*, and *PIK3CA* were acquired over the course of treatment. The acquisition of these mutations was associated with a longer time of treatment, and acquired mutations at the end of treatment correlated with a longer PFS. These data support the conclusion that driver mutations may be acquired later in therapy as a consequence of therapeutic pressures, but perhaps not always in the early treatment setting. These studies also suggest there may be limited clinical utility to stratify patients to treatment based on *ESR1* mutation status alone and that concurrent acquisition of other driver mutations may play a significant role in therapeutic resistance.

There are several considerations for the development of new targeted agents that may prove effective in suppressing *ESR1* mutant-bearing tumors. First, preclinical studies rely on the generation of *ESR1* mutation models through genetic manipulation using CRISPR/Cas9 or through overexpression systems, thus any results must be validated in patient-derived material. Patient-derived xenografts (PDX) can preserve clonal representation and are becoming a useful tool to study *ESR1* mutations and test new therapeutic strategies.⁴⁷ Indeed, several studies have shown treatment responses in PDX models in in vivo transplant experiments or ex vivo organoid culture strongly correlated to treatment responses seen in patients.⁴⁸⁻⁵⁰ Unfortunately, there is a paucity of ER-positive PDX models from MBC patients, especially patients with *ESR1* mutations. There is an urgent need to establish more mutation-positive PDX models from metastatic patients.

It is hoped that the development of novel oral and more potent SERDs will provide a more effective ET backbone to target WT and mutant ERs. Preclinical studies have shown the effectiveness of the newer SERDs

AZD9496, GDC-0810, and elacestrant (RAD1901) in reducing tumor growth of *ESR1* WT and mutant tumors.⁵¹⁻⁵⁴ AZD9496 exhibited higher activity against *ESR1* mutant cells than fulvestrant, as demonstrated through transcriptional and growth assays and in xenograft growth models. However, the short half-life of AZD9496 and reduced efficacy of GDC0810 are significant limitations for clinical development of these agents. Elacestrant is an orally available selective estrogen receptor degrader currently in phase 3 clinical trial to compare its efficacy and safety with standard of care ET (EMERALD trial; NCT03778931). Patients in this study who have WT or mutant *ESR1* and have progressed on up to 2 lines of ET with a CDK4/6 inhibitor were randomized to either elacestrant or standard of care ET (fulvestrant, anastrozole, letrozole, or exemestane). Preclinical studies demonstrated elacestrant inhibited both WT and mutant *ESR1* signaling and reduced the growth of mutant *ESR1*-bearing PDX models. If clinical studies demonstrate significant efficacy in the elacestrant arm, it would be one of the first clinically approved oral SERDs that may also be useful for patients with *ESR1* mutations.

Proteolysis targeting chimeras (PROTACs) are being developed to degrade the ER and may prove useful in patients who have ER-positive breast cancer.⁵⁵ PROTAC molecules contain an ER ligand covalently linked to an E3 ligase, which promotes proteasomal degradation of ER. Preclinical studies showed that the ER PROTAC ARV-471 promoted potent degradation of ER in multiple ER-positive cell line models.⁵⁶ Furthermore, ARV-471 showed robust growth inhibition of WT and mutant *ESR1* xenograft models. Clinical development of ARV-471 is ongoing and, if successful, will represent a novel class of ER protein degraders that can also be applied to targeting other proteins in breast and other cancers.

The development of additional targeted therapies for vulnerable pathways in breast cancer is needed to prolong progression and survival of patients with metastatic disease. Clinical trials using pan-PI3K inhibitors and isoform-specific inhibitors have been recently developed. A phase 1 trial in ER-positive MBC patients using the pan-PI3K inhibitor buparlisib in combination with fulvestrant showed that 2 patients with *ESR1* mutations derived clinic benefit.⁵⁷ Larger studies using fulvestrant with buparlisib, such as BELLE-2 and BELLE-3, are currently being evaluated. The BELLE-2 clinical trial was a phase 3 trial in which patients who had ER-positive breast cancer and progressed on AI therapy received either fulvestrant or fulvestrant plus buparlisib.⁵⁸ The BELLE-3

trial evaluated the efficacy of these therapies in patients who progressed after being treated with an mTOR inhibitor.⁵⁹ Although combinations exhibited a marginally better PFS (BELLE-2, 6.9 vs 5.0 months; BELLE-3, 3.9 vs 1.8 months) the toxicity profile of buparlisib plus fulvestrant does not support its further development in this setting. However, the use of isoform-specific PI3K inhibitors are showing promising clinical benefit. In the phase 3 SOALR-1 clinical trial, patients with ER-positive MBC who progressed on AI therapy were randomized to fulvestrant with or without the mutant PI3K- α specific inhibitor alpelisib.⁶⁰ Patients whose tumors contained *PIK3CA* mutations exhibited an improved PFS when treated with the combination of fulvestrant and alpelisib compared to fulvestrant monotherapy (11.1 vs 3.7 months). There was no significant difference in PFS for patients who had WT *PIK3CA*. In the SANDPIPER phase 3 clinical trial, where patients were randomized to receive either fulvestrant monotherapy or fulvestrant plus the mutant PI3K- α , β -sparing inhibitor taselisib, the addition of taselisib extended PFS by only 2 months compared with fulvestrant alone (7.4 vs 5.4 months) and was associated with more adverse events.⁶¹ Importantly, there has not yet been a retrospective analysis of *ESR1* mutations in these patient populations. Understanding whether these therapies can effectively target tumors with *ESR1* mutations, or prevent the acquisition or subclonal evolution of these mutations, could provide alternative treatments for patients with *ESR1* mutations.

AKT inhibitors may be another approach for targeting patients with *ESR1* mutations, since this pathway can be activated. A single-arm, phase 2 neoadjuvant clinical trial was conducted using the AKT inhibitor MK-2206 in combination with anastrozole in advanced breast cancer patients with a *PIK3CA* mutation.⁶² There were no pathological complete responses (pCR) in the ER-positive population, and there was no additional suppression of tumor cell proliferation with the addition of MK-2206.⁶² Furthermore, a patient in this study acquired an *ESR1* mutation detected at the time of surgery. Although not statistically powered for analysis, this observation could suggest clinical resistance of *ESR1* mutations to AKT inhibitors. This is an important clinical question to be resolved. Another phase 2/3 clinical trial, IPATunity130 (NCT03337724), is investigating the use of the AKT inhibitor ipatasertib in combination with paclitaxel to determine whether patients with advanced or ER-positive MBC or TNBC who have a genomic alteration in *PIK3CA*, *AKT1*, or *PTEN* will benefit from AKT inhibition. The LOTUS phase 2 clinical trial found

that patients with TNBC treated with ipatasertib and paclitaxel had improved PFS compared with paclitaxel alone (6.2 vs 4.9 months),⁶³ providing the rationale for IPATunity130. It will be valuable to determine whether ER-positive breast cancer patients in this trial will also derive benefit from this combination. However, mTOR inhibitors currently remain the best option for treating ER-positive patients with activation of the PI3K/AKT/mTOR pathway.

The combination of fulvestrant and everolimus has been tested in the PrE0102 (NCT01797120) clinical trial, where patients with ER-positive, AI-resistant MBC were treated with fulvestrant, with or without everolimus.⁶⁴ Patients treated with the combination showed a significant extension of PFS compared with fulvestrant alone (10.3 vs 5.1 months). However, there are no projected differences in overall survival. These results demonstrate that targeting the PI3K pathway through PI3K- or mTOR-selective inhibitors may be clinically useful; however, further investigation is needed to determine whether patients with *ESR1* mutations derive benefit from these combinations.

Immunotherapy using checkpoint inhibitors is approved for many cancers, including melanoma, lung cancer, and bladder cancer. In recent years, antibodies to PD-L1, PD-1, or CTLA4 have been developed to target immune-suppressive pathways, allowing for cytotoxic T cells to infiltrate and kill tumor cells.^{65,66} In breast cancer, immunotherapy clinical trials have been mainly focused on metastatic TNBC, a genomically unstable subtype of breast cancer that is believed to be the most immunogenic.^{67,68} The multicenter I-SPY 2, phase 2 clinical trial is evaluating novel neoadjuvant therapies and comparing immune therapy in combination with chemotherapy. In TNBC, there were higher pCR rates in patients treated with the combination of the anti-PD-1 therapy pembrolizumab with paclitaxel compared with paclitaxel treatment alone (approximately 60% vs 20%).⁶⁹ In ER-positive/HER2-negative breast cancers, there was also an increase in pCR in patients treated with the pembrolizumab-containing regimen (approximately 34% vs. 13%). Furthermore, in the phase 1 KEYNOTE-028 clinical trial, in which ER-positive breast cancer patients were treated with pembrolizumab monotherapy after progressing on several lines of therapies (median of 9 therapies before pembrolizumab treatment), 20% (5/25) attained a partial response and 52% (13/25) had stable disease. Pembrolizumab is currently being tested in combination with fulvestrant in MBC patients (NCT03393845) and

may provide insight into the efficacy of immunotherapies in first- or second-line metastatic disease.

Because many patients with ER-positive MBC will be treated with a CDK4/6 inhibitor, it is important to understand how systemic inhibition of CDK4/6 alters immunotherapy responses. A recent study reported that CDK4/6 inhibitors enhanced PD-L1 expression on tumor cells and augmented responsiveness to PD-L1 immune therapy.⁷⁰ In a separate study, it was demonstrated that systemic CDK4/6 inhibition resulted in suppression of regulatory T cells, but had a lesser effect on CD8+ T cells, suggesting there may be an enhanced T cell-mediated antitumor response.⁷¹ These preclinical data suggest that systemic CDK4/6 inhibition may upregulate PD-L1 expression on tumor cells and inhibit regulatory T cells, which may augment responses to immunotherapy in patients after or during treatment with CDK4/6 inhibitors. The Palbociclib After CDK Inhibitor and ET (PACE) phase 2 clinical trial (NCT03147287) is testing the efficacy of combining ET, CDK4/6 inhibition, and a PD-1 inhibitor in MBC patients who have progressed on ET. Furthermore, because *ESR1* mutant cells have been shown to upregulate pathways involved in inflammatory response,²⁰ it is possible that tumors expressing *ESR1* mutations may be sensitive to immunotherapies. Analysis of *ESR1* mutations in patients being treated in these clinical trials should be performed to determine whether these therapies prevent the acquisition of *ESR1* mutations during therapy.

PRECLINICAL STRATEGIES TO IDENTIFY ACTIONABLE TARGETS IN *ESR1* MUTANT BREAST CANCER

Genome-wide CRISPR knockout screens and transcriptomic analyses identified several genes that are essential for growth of *ESR1* mutant tumors.²⁰ Potential candidates identified in these preclinical studies are classified as ER coregulators, kinases, and receptors involved in growth factor signaling and downstream ER phosphorylation and epigenetic modifying proteins (Table 2).^{14,18,20,21,24,57,72-75} Importantly, many of these proteins are targetable, and combinations of specific inhibitors and ET have either an additive or synergistic growth reduction in preclinical models.

The identification of mutant-selective coregulators is one strategy to target mutant ER transcriptional activity. Gates et al¹⁸ performed mass spectrometry-based proteomic profiling of WT, Y537S, and D538G protein complexes to identify coactivators for mutant

TABLE 2. Potential Therapeutic Targets Discovered in Preclinical Studies for Treating *ESR1* Mutant-Bearing Tumors

Target Name	Targeted Therapy	Reference
CDK7	THZ1	Jeselson et al, ²⁰ Harrod et al ²¹
BET family	JQ1	Ladd et al ⁷²
Class I and II HDAC	Vorinostat	Ladd et al ⁷²
SRC-3	SI-2	Gates et al ¹⁸
CDK2	Dinaciclib	Scott et al ⁷³
IGF-1R	OSI-906	Gelsomino et al, ¹⁴ Li et al ²⁴
UPR	BHPI	Mao et al ⁷⁴
NOTCH	RO4929097	Gelsomino et al ⁷⁵

ER. Pharmacological inhibition of the coactivator SRC-3 in combination with ET synergistically reduced ER transcriptional activity and growth of mutant ER-expressing models. Furthermore, the SRC inhibitor SI-2 in combination with AZD9496 significantly inhibited growth of a Y537S *ESR1* mutant PDX model in vivo, suggesting that the SRC family of coactivators may be useful therapeutic targets for blocking mutant ER growth.

In addition to targeting ER coregulators, several studies have shown that targeting kinases that phosphorylate mutant ER can augment growth inhibition by ET. CDK7 phosphorylates ER at S118 and is also required for cell cycle progression.⁷⁶ In a study reported by Harrod et al,²¹ the selective CDK7 inhibitor THZ1 significantly reduced the growth of MCF-7 cells expressing the Y537S *ESR1* mutation. The combination of THZ1 with fulvestrant resulted in further decreased growth, reduction of S118 phosphorylation, and reduction of ER-mediated gene expression. Jeselson et al²⁰ confirmed these findings, and also reported that the growth of MCF-7 *ESR1* Y537S xenograft tumors were significantly reduced with fulvestrant in combination with THZ1. A study reported by Scott et al⁷³ reported that CDK2 can phosphorylate ER serine 294, which led to ligand-independent ER-mediated gene transcription. ER S294 was also found to be hyper-phosphorylated in MCF-7 *ESR1* Y537S and D538G cells compared with WT *ESR1* cells. Treatment with the CDK2 inhibitor dinaciclib resulted in a reduction of S294 phosphorylation, and in combination with tamoxifen resulted in tumor regression in a MCF-7 *ESR1* Y537S xenograft model. These data demonstrate that inhibition of selective CDKs, such as CDK7 and CDK2, could potentially benefit patients with *ESR1* mutations and supports their clinical development of these alternative treatment approaches.

ESR1 mutant models have been used to demonstrate other potential targetable pathways, such as the unfolded protein response (UPR) and stemness pathways. Mao et al⁷⁴ showed that Y537S and D538G mutant cells have constitutive hyperactivation of the UPR pathway, and that this may contribute to the ET-resistant phenotype of *ESR1* Y537S and D538G mutant cells. The ER biomodulator BHPI activates UPR, which causes inhibition of protein synthesis and cell death. Treatment of T47D *ESR1* WT and mutant cells with BHPI decreased estrogen-stimulated growth and further enhanced growth reduction with tamoxifen or fulvestrant. Furthermore, activation of progesterone receptor with progestin was associated with increased resistance to anti-estrogen therapies and further activation of the UPR pathway in *ESR1* mutant cells as measured by downstream markers, such as spliced XBP1. Treatment with BHPI reduced progestin-stimulated growth. Collectively, this study demonstrated that UPR activation contributes to the ET-resistant phenotype associated with *ESR1* mutation expression. Gelsomino et al⁷⁵ demonstrated that the Y537S *ESR1* mutation increases a stem cell-like phenotype. Y537S *ESR1* mutant cells exhibited a higher percentage of CD44+/CD24− cells compared with WT *ESR1* cells and had enhanced Notch signaling, indicating that these cells represent a more stem-like progenitor. Therapeutic screening of stem cell pathway inhibitors enhanced Notch signaling in *ESR1* mutant cells, which was mediated through phosphorylation of residue S118 in Y537S ER. Furthermore, inhibition of Notch signaling using the RO4929097 selective inhibitor reduced mammosphere formation efficiency, but inhibitors of other stem cell pathways such as the Wnt/B-catenin and sonic hedgehog were not effective. These collective results show that *ESR1* mutant cells have enriched stem cell properties through Notch signaling and that this pathway could be potentially targeted in patients with *ESR1* mutant-expressing tumors.

An additional novel strategy to overcome ET resistance is to therapeutically target epigenetic modifying proteins to either inhibit ER transcriptional activity or resensitize tumor cells to ET by modifying ER expression and chromatin binding. The JQ1 inhibitor targets the BET family of bromodomain proteins, and the HDAC inhibitor vorinostat has been tested in an *ESR1* D538G model and demonstrated effective reduction of tumor growth and ER transcriptional activity when treated in combination with fulvestrant.⁷² Unfortunately, the BET inhibitors have shown widespread toxicity in clinical trials. The efficacy of the HDAC inhibitor entinostat has been tested in clinical

trials in combination with ET. In the phase 2 ENCORE301 trial, patients with ER-positive advanced breast cancer were treated with either exemestane or in combination with entinostat.^{77,78} There was an improvement in PFS (4.3 vs 2.3 months) and OS (28.1 vs 19.8 months) with the combination, leading to the initiation of the larger phase 3 E2112 trial (NCT02115282).⁷⁹ Because preclinical studies suggest that *ESR1* mutant cells are sensitive to HDAC inhibition in combination with ET, it would be valuable to see whether clinical trials with tamoxifen or fulvestrant can be developed further and whether patients with *ESR1* mutations derive benefit from these combinations. Figure 2 shows potential targetable pathways in *ESR1*m tumors and highlights several inhibitors used in preclinical and clinical studies to target these pathways. However, use of the PI3K inhibitors alpelisib and taselisib will have to be evaluated further to determine whether patients with *ESR1* mutant-bearing tumors derive clinical benefit. These studies demonstrate there are several new targets that could potentially be actionable in the clinic; however, there is an urgent need to continue developing clinical trials of inhibitors of these novel targets.

An additional consideration for the development of effective therapies to target *ESR1* mutant tumors will be to target common acquired mechanisms of resistance between mutant and WT ER. The majority of patients with advanced or ER-positive MBC will be treated with a CDK4/6 or mTOR inhibitor in combination with ET during the course of their disease. Indeed, several studies now demonstrate differential mechanisms of acquired resistance to either mTOR or CDK4/6 inhibitors in breast and other cancers, including upregulation of MAPK signaling in everolimus- and palbociclib-resistant models, as well as mutations in *RBI*, and upregulation of *CDK2*, *CCNE1*, or *PDK1* in palbociclib-resistant cells.^{80–86} These aberrations associated with targeted therapy resistance could be used to develop an effective treatment sequence to delay disease progression. Certainly, several recent and ongoing clinical trials testing investigational agents are recruiting patients who have been treated previously with mTOR or CDK4/6 inhibitors, and comparison of response between these patient populations is necessary to provide insight into whether certain patient populations benefit from sequencing of targeted therapies or are inherently resistant to therapy.

Conclusions

Collectively, it has been demonstrated that *ESR1* mutations are frequently acquired during AI therapy in the metastatic setting and may play a role in metastatic




Figure 2. Targetable pathways in *ESR1* mutant cells identified in preclinical studies. Growth factor receptor (GFR) signaling through insulinlike growth factor 1R activates the PI3K pathway, which is inhibited with GFR inhibitors or PI3K inhibitors. Cyclin-dependent kinases 2 and 7 phosphorylate and activate estrogen receptor (ER). NOTCH, histone deacetylase, BET family proteins, ER coactivators, or ER itself are altered and implicated in resistance of ER mutant cancers. Immunotherapies targeting PD-1 are currently being investigated in breast cancer clinical trials. CDK, cyclin-dependent kinase; CoA, coactivator; EnR, endoplasmic reticulum; GFRs, growth factor receptors; HDAC, histone deacetylase; IGF, insulinlike growth factor; MHC, major histocompatibility complex; mTOR, mammalian target of rapamycin; TCR, T cell receptor.

progression. Advances in DNA sequencing technology have led to more sensitive detection of *ESR1* mutations in clinical samples, and there are now several studies applying sequencing and ddPCR methods to track *ESR1* and other mutations during treatment and progression. Targeted DNA sequencing and ddPCR technologies have shown that *ESR1* mutations can pre-exist in approximately 5% of primary tumors and are significantly enriched by 30% to 40% in the metastatic setting. Analysis of ctDNA allows for an easy, noninvasive, and relatively inexpensive method to monitor driver mutations that may arise during treatment, which may eventually be used to guide treatment decisions. Importantly, monitoring *ESR1* mutations alone has not been clinically predictive of treatment; however, monitoring the acquisition of truncal or other mutations may predict response and/or progression of treated cancers. Currently, patients who have tumors

expressing *ESR1* mutations are best treated with the combination of fulvestrant and palbociclib, since this combination has significantly improved PFS in patients with the majority of identified *ESR1* mutations. Ongoing clinical trials using fulvestrant with PI3K- α specific inhibitors are showing promising clinical results, but the analysis of whether patients with specific *ESR1* mutations will benefit from this treatment have yet to be published. Furthermore, immunotherapies are becoming increasingly more effective in solid tumors, and it is hoped that ongoing clinical trials may show clinical benefit in selected ER-positive MBC patients. Preclinical studies have identified novel targets that may be clinically important for targeting in these patients. Further discovery and development of targeted inhibitors is needed, and ongoing and future clinical trials are necessary to discover new treatment options for patients with MBC.

FUNDING SUPPORT

This work was supported by National Cancer Institute (grants R01-CA72038, R01-CA207270), the Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award (RP120732), the Breast Cancer Research Foundation (grant 18-055), and NIH NCI (grant 5P30 CA125123).

CONFLICT OF INTEREST DISCLOSURES

The authors made no disclosures.

REFERENCES

- American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta, GA: American Cancer Society; 2017.
- Barone I, Iacopetta D, Covington KR, et al. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. *Oncogene*. 2010;29:2404-2414.
- Fuqua SA, Gu G, Rechoum Y. Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. *Breast Cancer Res Treat*. 2014;144:11-19.
- Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. *Cancer Cell*. 2018;34:427-438.
- Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med*. 2015;373:209-219.
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*. 2016;375:1925-1936.
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*. 2016;375:1738-1748.
- Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*. 2017;35:3638-3646.
- Fribbens C, O'Leary B, Kilburn L, et al. Plasma *ESR1* mutations and the treatment of estrogen receptor-positive advanced breast cancer. *J Clin Oncol*. 2016;34:2961-2968.
- Chandarlapaty S, Chen D, He W, et al. Prevalence of *ESR1* mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. *JAMA Oncol*. 2016;2:1310-1315.
- Fuqua SA, Wiltshcke C, Zhang QX, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. *Cancer Res*. 2000;60:4026-4029.
- Toy W, Weir H, Razavi P, et al. Activating *ESR1* mutations differentially affect the efficacy of ER antagonists. *Cancer Discov*. 2017;7:277-287.
- Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. *Cancer Res*. 1997;57:1244-1249.
- Gelsomino L, Gu G, Rechoum Y, et al. *ESR1* mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. *Breast Cancer Res Treat*. 2016;157:253-265.
- Toy W, Shen Y, Won H, et al. *ESR1* ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet*. 2013;45:1439-1445.
- Robinson DR, Wu YM, Vats P, et al. Activating *ESR1* mutations in hormone-resistant metastatic breast cancer. *Nat Genet*. 2013;45:1446-1451.
- Pavlin M, Spinello A, Pennati M, et al. A computational assay of estrogen receptor alpha antagonists reveals the key common structural traits of drugs effectively fighting refractory breast cancers. *Sci Rep*. 2018;8:649.
- Gates LA, Gu G, Chen Y, et al. Proteomic profiling identifies key coactivators utilized by mutant ERalpha proteins as potential new therapeutic targets. *Oncogene*. 2018;37:4581-4598.
- Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. *Cancer Res*. 2013;73:6856-6864.
- Jeselson R, Bergholz JS, Pun M, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of *ESR1* activating mutations. *Cancer Cell*. 2018;33:173-186.
- Harrod A, Fulton J, Nguyen VTM, et al. Genomic modelling of the *ESR1* Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. *Oncogene*. 2017;36:2286-2296.
- Bahreini A, Li Z, Wang P, et al. Mutation site and context dependent effects of *ESR1* mutation in genome-edited breast cancer cell models. *Breast Cancer Res*. 2017;19:60.
- Martin LA, Ribas R, Simigdala N, et al. Discovery of naturally occurring *ESR1* mutations in breast cancer cell lines modelling endocrine resistance. *Nat Commun*. 2017;8:1865.
- Li Z, Levine KM, Bahreini A, et al. Upregulation of IRS1 enhances IGF1 response in Y537S and D538G *ESR1* mutant breast cancer cells. *Endocrinology*. 2018;159:285-296.
- Gu G, Rechoum Y, Gelsomino L, et al. The Y537S *ESR1* mutation is a dominant driver of distant ER-positive breast cancer metastasis. Abstract presented at: San Antonio Breast Cancer Symposium 2016; December 6-10, 2016; San Antonio, TX.
- Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of *ESR1* mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. *Sci Transl Med*. 2015;7:313ra182.
- Clatot F, Perdrix A, Augusto L, et al. Kinetics, prognostic and predictive values of *ESR1* circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. *Oncotarget*. 2016;7:74448-74459.
- Spørke JM, Gendreau S, Walter K, et al. Heterogeneity and clinical significance of *ESR1* mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. *Nat Commun*. 2016;7:11579.
- Andre F, Filleron T, Ng C, et al. Genomic characterization of metastatic breast cancers. Abstract presented at: San Antonio Breast Cancer Symposium 2018; December 4-10, 2018; San Antonio, TX.
- Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Droplet digital polymerase chain reaction assay for screening of *ESR1* mutations in 325 breast cancer specimens. *Transl Res*. 2015;166:540-553.
- Liang X, Briault A, Becette V, et al. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). *J Hematol Oncol*. 2018;11:124.
- Shaw JA, Guttery DS, Hills A, et al. Mutation analysis of cell-free dna and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. *Clin Cancer Res*. 2017;23:88-96.
- Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*. 2012;366:520-529.
- Fribbens C, Garcia Murillas I, Beaney M, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. *Ann Oncol*. 2018;29:145-153.
- Chung JH, Pavlick D, Hartmaier R, et al. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. *Ann Oncol*. 2017;28:2866-2873.
- Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Comparison of *ESR1* mutations in tumor tissue and matched plasma samples from metastatic breast cancer patients. *Transl Oncol*. 2017;10:766-771.
- Wang P, Bahreini A, Gyanchandani R, et al. Sensitive detection of mono- and polyclonal *ESR1* mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. *Clin Cancer Res*. 2016;22:1130-1137.
- Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. *Lancet Oncol*. 2013;14:989-998.
- O'Leary B, Cutts RJ, Liu Y, et al. The Genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. *Cancer Discov*. 2018;8:1390-1403.
- Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2016;17:811-821.
- Cristofanilli M, DeMichele A, Giorgetti C, et al. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with

- endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. *Eur J Cancer*. 2018;104:21-31.
42. O'Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. *Nat Commun*. 2018;9:896.
 43. Lok SW, Whittle JR, Vaillant F, et al. A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer. *Cancer Discov*. 2019;9:354-369.
 44. Allouchery V, Beaussire L, Perdrix A, et al. Circulating *ESR1* mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. *Breast Cancer Res*. 2018;20:40.
 45. Ma CX, Sparano JA. Treatment approach to metastatic hormone receptor-positive, HER2-negative breast cancer: endocrine therapy and targeted agents. <https://www.upToDate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-her2-negative-breast-cancer-endocrine-therapy-and-targeted-agents>. Accessed December 18, 2018.
 46. Finn RS, Dieras V, Rugo HS, et al. Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy and safety across patient (pt) subgroups. *J Clin Oncol*. 2017;35:1039-1039.
 47. Li S, Shen D, Shao J, et al. Endocrine-therapy-resistant *ESR1* variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Rep*. 2013;4:1116-1130.
 48. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Mol Cancer Ther*. 2011;10:1311-1316.
 49. Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat Med*. 2015;21:1318-1325.
 50. Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H. Personalized cancer medicine: an organoid approach. *Trends Biotechnol*. 2018;36:358-371.
 51. Weir HM, Bradbury RH, Lawson M, et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and *ESR1*-mutant breast tumors in preclinical models. *Cancer Res*. 2016;76:3307-3318.
 52. Joseph JD, Darimont B, Zhou W, et al. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. *Elife*. 2016;5.
 53. Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models. *Clin Cancer Res*. 2017;23:4793-4804.
 54. Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. *Anticancer Drugs*. 2015;26:948-956.
 55. Wang L, Guillen VS, Sharma N, et al. New class of selective estrogen receptor degraders (SERDs): expanding the toolbox of PROTAC degrons. *ACS Med Chem Lett*. 2018;9:803-808.
 56. Flanagan J, Qian Y, Gough S, et al. ARV-471, an oral estrogen receptor PROTAC™ protein degrader for breast cancer. Abstract presented at: San Antonio Breast Cancer Symposium 2018; December 4-10, 2018; San Antonio, TX.
 57. Ma CX, Luo J, Naughton M, et al. A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. *Clin Cancer Res*. 2016;22:1583-1591.
 58. Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2017;18:904-916.
 59. Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2018;19:87-100.
 60. Andre F. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase 3 SOLAR-1 trial [abstract LBA3_PR]. Abstract presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany.
 61. Baselga J, Faye Dent S, Cortes J, et al. Phase III study of taselisib (GDC-0032) plus fulvestrant versus fulvestrant in patients with estrogen receptor-positive, PIK3CA-mutant, locally advanced or metastatic breast cancer: primary analysis from SANDPIPER [abstract LBA1006]. *J Clin Oncol*. 2018;36.
 62. Ma CX, Suman V, Goetz MP, et al. A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer. *Clin Cancer Res*. 2017;23:6823-6832.
 63. Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2017;18:1360-1372.
 64. Kornblum N, Zhao F, Manola J, et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. *J Clin Oncol*. 2018;36:1556-1563.
 65. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. *Clin Cancer Res*. 2013;19:1021-1034.
 66. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. *Front Oncol*. 2018;8:86.
 67. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. *Breast Cancer Res*. 2012;14:R48.
 68. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol*. 2013;31:860-867.
 69. Nanda R, Liu M, Yao C, Asare S, Hylton N, Van't Veer L. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2 [abstract 506]. *J Clin Oncol*. 2017;35.
 70. Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. *Nature*. 2018;553:91-95.
 71. Deng J, Wang ES, Jenkins RW, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. *Cancer Discov*. 2018;8:216-233.
 72. Ladd B, Mazzola AM, Bihani T, et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. *Oncotarget*. 2016;7:54120-54136.
 73. Scott GK, Chu D, Kaur R, et al. ERp294 is a biomarker of ligand or mutational ERalpha activation and a breast cancer target for CDK2 inhibition. *Oncotarget*. 2017;8:83432-83445.
 74. Mao C, Livezey M, Kim JE, Shapiro DJ. Antiestrogen resistant cell lines expressing estrogen receptor alpha mutations upregulate the unfolded protein response and are killed by BHPI. *Sci Rep*. 2016;6:34753.
 75. Gelsomino L, Panza S, Giordano C, et al. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines. *Cancer Lett*. 2018;428:12-20.
 76. Chen D, Riedl T, Washbrook E, et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIF and participation of CDK7. *Mol Cell*. 2000;6:127-137.
 77. Yardley D, Ismail-Khan R, Klein P. Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI). *J Clin Oncol*. 2011;29:268.
 78. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing

- on treatment with a nonsteroidal aromatase inhibitor. *J Clin Oncol*. 2013;31:2128-2135.
79. Yeruva SLH, Zhao F, Miller KD, et al. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. *NPJ Breast Cancer*. 2018;4:1.
80. Kimura M, Hanamura T, Tsuboi K, et al. Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer. *Oncotarget*. 2018;9:21468-21477.
81. Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. *Cancer Res*. 2016;76:2301-2313.
82. Condorelli R, Spring L, O'Shaughnessy J, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. *Ann Oncol*. 2018;29:640-645.
83. de Leeuw R, McNair C, Schiewer MJ, et al. MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer. *Clin Cancer Res*. 2018;24:4201-4214.
84. Jansen VM, Bhola NE, Bauer JA, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. *Cancer Res*. 2017;77:2488-2499.
85. Malorni L, Piazza S, Ciani Y, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. *Oncotarget*. 2016;7:68012-68022.
86. Min A, Kim JE, Kim YJ, et al. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. *Cancer Lett*. 2018;430:123-132.